News | May 14, 2022
CCMB develops India’s first mRNA vaccine technology
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Both companies have been selected for stand-by production by German government
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Subscribe To Our Newsletter & Stay Updated
